Welcome to our dedicated page for Averin Cap Acquisition SEC filings (Ticker: ACAAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Averin Cap Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Averin Cap Acquisition's regulatory disclosures and financial reporting.
Averin Capital Acquisition Corp. appointed Akiko Moni Miyashita to its board of directors, effective May 28, 2026. She will serve in the first class of directors, with a term ending at the company’s first annual general meeting.
Miyashita, age 70, is the Founder of Beacon Hill Strategy Group since October 2024 and has more than 25 years of experience in strategy, finance and corporate development across healthcare, life sciences, technology and global markets. Her prior roles include Executive Vice President and Chief Strategy Officer at Valo Health, Senior Advisor at McKinsey & Company, Partner at Innosight, and Vice President of Corporate Development at IBM.
In connection with her appointment, she joined an existing letter agreement and a registration rights agreement, agreeing to waive certain redemption rights, vote her ordinary shares in favor of an initial business combination, and receive registration rights for any company shares she owns. She also entered into a standard director indemnity agreement with Averin Capital Acquisition Corp.
Averin Capital Acquisition Corp. appointed Akiko Moni Miyashita to its board of directors, effective May 28, 2026. She will serve in the first class of directors, with a term ending at the company’s first annual general meeting.
Miyashita, age 70, is the Founder of Beacon Hill Strategy Group since October 2024 and has more than 25 years of experience in strategy, finance and corporate development across healthcare, life sciences, technology and global markets. Her prior roles include Executive Vice President and Chief Strategy Officer at Valo Health, Senior Advisor at McKinsey & Company, Partner at Innosight, and Vice President of Corporate Development at IBM.
In connection with her appointment, she joined an existing letter agreement and a registration rights agreement, agreeing to waive certain redemption rights, vote her ordinary shares in favor of an initial business combination, and receive registration rights for any company shares she owns. She also entered into a standard director indemnity agreement with Averin Capital Acquisition Corp.
Averin Capital Acquisition Corp. director Miyashita Akiko Moni has filed an initial Form 3 as a reporting person for the company. The filing does not list any share transactions or derivative positions, indicating it is a baseline disclosure of insider status rather than a record of recent trading activity.
Averin Capital Acquisition Corp. director Miyashita Akiko Moni has filed an initial Form 3 as a reporting person for the company. The filing does not list any share transactions or derivative positions, indicating it is a baseline disclosure of insider status rather than a record of recent trading activity.
Averin Capital Acquisition Corp., a SPAC focused on technology and health, reported net income of $832,500 for the three months ended March 31, 2026, mainly from $987,118 of interest on funds in its trust account. Total assets were $285.5M, including $284.8M of investments in the Trust Account backing 28,386,008 Class A shares subject to redemption at about $10.03 per share. The SPAC raised $283.9M through its IPO, over-allotment and private placement, and has a deferred underwriting fee of $15.6M payable upon completing a business combination. Management discloses substantial doubt about the company’s ability to continue as a going concern due to limited working capital and the requirement to complete a business combination by February 20, 2028 (or May 20, 2028 with a signed deal) or liquidate.
Averin Capital Acquisition Corp., a SPAC focused on technology and health, reported net income of $832,500 for the three months ended March 31, 2026, mainly from $987,118 of interest on funds in its trust account. Total assets were $285.5M, including $284.8M of investments in the Trust Account backing 28,386,008 Class A shares subject to redemption at about $10.03 per share. The SPAC raised $283.9M through its IPO, over-allotment and private placement, and has a deferred underwriting fee of $15.6M payable upon completing a business combination. Management discloses substantial doubt about the company’s ability to continue as a going concern due to limited working capital and the requirement to complete a business combination by February 20, 2028 (or May 20, 2028 with a signed deal) or liquidate.
Averin Capital Acquisition Corp. Schedule 13G reports that Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, beneficially own 2,250,000 Class A ordinary shares, representing 8.93% of the Class A shares outstanding. The percentage is calculated on 25,200,000 shares outstanding as of February 20, 2026.
The filing states shared voting and dispositive power of 2,250,000 shares for each Reporting Person and includes a Joint Filing Agreement in Exhibit 99.1.
Averin Capital Acquisition Corp. Schedule 13G reports that Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, beneficially own 2,250,000 Class A ordinary shares, representing 8.93% of the Class A shares outstanding. The percentage is calculated on 25,200,000 shares outstanding as of February 20, 2026.
The filing states shared voting and dispositive power of 2,250,000 shares for each Reporting Person and includes a Joint Filing Agreement in Exhibit 99.1.